Clinical Pharmacist Intervention to Reduce Drug-related Readmissions Among Older People
Launched by UMEÅ UNIVERSITY · Sep 13, 2018
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at whether a special program involving clinical pharmacists can help reduce hospital readmissions caused by medication issues in patients over 75 years old. The focus is on improving the transfer of care from the hospital back to regular doctors. During the study, pharmacists will review medical charts and talk with patients over a period of 180 days to ensure they understand their medications and how to take them safely.
To be eligible for this trial, patients must live at home, have been recently admitted to the hospital, and be registered at one of ten specific primary care centers. Unfortunately, those who cannot communicate well, are scheduled for end-of-life care, or were admitted due to drug or alcohol use will not be able to participate. If you or a loved one qualify, you can expect to receive personalized help from pharmacists aimed at making sure medications are managed properly, which could lead to fewer trips back to the hospital.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Living at home
- • Acutely admitted
- • Registered at one of ten pre-specified primary care health centers
- Exclusion Criteria:
- • Patients unable to communicate or who do not speak Swedish
- • Patients scheduled for palliative care
- • Patients admitted due to intoxication by alcohol or drug (non prescription)
About Umeå University
Umeå University, a leading research institution in Sweden, is dedicated to advancing healthcare through innovative clinical trials and translational research. With a strong emphasis on interdisciplinary collaboration, the university harnesses cutting-edge technology and expert knowledge across various fields to address critical health challenges. Its commitment to ethical standards and patient safety ensures that all clinical trials conducted under its auspices are designed to generate robust scientific evidence, ultimately contributing to improved health outcomes and informed medical practices. Umeå University strives to foster a dynamic research environment that supports the development of new therapies and enhances the understanding of complex health issues.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Umeå, , Sweden
Patients applied
Trial Officials
Maria Gustafsson, Ph.D
Principal Investigator
Umeå University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials